Akzo Signed Biotech Supply Agreement
Akzo Nobel's Diosynth Biotechnology business has signed a supply agreement with the Dutch-based Pharming Group for the production of recombinant human C1 inhibitor (rhC1INH) for commercial use. The agreement enables Pharming to prepare for the market launch of rhC1INH for the treatment of hereditary angioedema, a life threatening genetic disorder caused by a deficiency of the C1 inhibitor protein.
Under the terms of the deal, Diosynth Biotechnology is responsible for technology transfer, purification-process development, scaling-up and the commercial production of Pharming's rhC1INH at its large-scale downstream processing facility in Oss, the Netherlands. The facility has been FDA inspected and currently produces commercial products. The financial terms of the agreement have not been disclosed.
Topics
Organizations
Other news from the department business & finance

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
More news from our other portals
Last viewed contents
Tecan and the Monash Antibody Technologies Facility unveil custom monoclonal antibody production facility
Acacia Pharma starts clinical trial with APD515 for Xerostomia

Innovative therapeutic tools in the fight against cancer - Spin-off company of the University Medical Center Mainz starts operations and enters into joint venture with Indivumed
Cardio3 BioSciences Appoints Dr. Alexander Milstein as Vice President of Clinical Development
Dr. Andrew Zhu Joins Chemokine Therapeutics' Clinical Advisory Board
Gilead Sciences to Acquire Pharmasset, Inc. for $11 Billion
MediGene Initiates Clinical Formulation Study of RhuDex for the Oral Treatment of Autoimmune Diseases
